Top Page
BioCryst
(NASDAQ:BCRX)
BioCryst (BCRX) vs. SPDR S&P 500 ETF (SPY)
BioCryst Business Overview & Revenue Model
BioCryst Key Performance Indicators (KPIs)
Analyzes revenue from different business segments, offering insight into which parts of BioCryst's operations are most profitable and where there may be opportunities or challenges.
Main Street DataBioCryst Earnings Call Summary
BioCryst Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 503.49M | 450.71M | 331.41M | 270.83M | 157.17M | 17.81M |
| Gross Profit | 487.82M | 438.44M | 325.10M | 262.80M | 149.13M | 16.14M |
| EBITDA | 40.45M | 12.81M | -116.33M | -143.85M | -121.74M | -167.56M |
| Net Income | -53.47M | -88.88M | -226.54M | -247.12M | -184.06M | -182.81M |
Balance Sheet | ||||||
| Total Assets | 480.05M | 490.42M | 516.96M | 550.00M | 588.15M | 334.71M |
| Cash, Cash Equivalents and Short-Term Investments | 295.09M | 320.85M | 388.99M | 424.31M | 507.60M | 300.37M |
| Total Debt | 794.99M | 808.74M | 848.71M | 741.45M | 593.24M | 279.50M |
| Total Liabilities | 931.97M | 966.35M | 972.49M | 844.60M | 695.14M | 353.98M |
| Stockholders Equity | -451.93M | -475.93M | -455.53M | -294.60M | -106.99M | -19.26M |
Cash Flow | ||||||
| Free Cash Flow | -27.29M | -53.14M | -97.31M | -163.20M | -144.54M | -137.73M |
| Operating Cash Flow | -26.25M | -52.02M | -95.14M | -161.85M | -142.16M | -137.22M |
| Investing Cash Flow | 50.93M | 52.59M | -131.50M | -128.24M | 15.80M | -6.86M |
| Financing Cash Flow | -4.18M | -5.76M | 32.48M | 88.03M | 359.67M | 300.59M |
BioCryst Technical Analysis
BioCryst Risk Analysis
BioCryst Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $1.09B | 36.11 | -35.00% | ― | 32.50% | 236.33% | |
62 Neutral | $2.09B | 3.20 | 60.26% | ― | 25.96% | ― | |
60 Neutral | $3.12B | ― | -32.17% | ― | -25.85% | -23.89% | |
53 Neutral | $2.32B | ― | -24.67% | ― | 1436.97% | 68.03% | |
52 Neutral | $7.50B | 0.31 | -61.87% | 2.27% | 17.10% | 1.59% | |
46 Neutral | $1.87B | ― | 18.68% | ― | 41.67% | 75.79% | |
43 Neutral | $1.84B | ― | -23.34% | ― | ― | -14.19% |
BioCryst Corporate Events
On June 27, 2025, BioCryst Pharmaceuticals entered into a Stock Purchase Agreement to sell its equity interests in BioCryst Ireland to Neopharmed Gentili S.p.A. for $250 million, with potential additional payments based on revenue milestones. This transaction, expected to close in October 2025, will involve amendments to existing intellectual property agreements and establish BioCryst as the exclusive supplier of ORLADEYO® to the company, impacting BioCryst’s operations and market positioning in Europe.
The most recent analyst rating on (BCRX) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.
On June 27, 2025, BioCryst Pharmaceuticals announced the sale of its European ORLADEYO business to Neopharmed Gentili for up to $264 million. The transaction will allow BioCryst to eliminate its remaining term debt, saving approximately $70 million in future interest payments, and is expected to leave the company with $700 million in cash by the end of 2027. This strategic move aligns with BioCryst’s goal of enhancing profitability and sustaining growth, while Neopharmed Gentili aims to strengthen its position in the European specialty pharmaceutical market.
The most recent analyst rating on (BCRX) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.
On June 23, 2025, the FDA extended the PDUFA goal date for BioCryst‘s new drug application for ORLADEYO® oral granules for pediatric HAE patients aged 2 to 11. This extension, moving the target action date to December 12, 2025, was due to the submission of additional reports and data, which the FDA considered a major amendment requiring a full review.
The most recent analyst rating on (BCRX) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.
On June 11, 2025, George B. Abercrombie announced his retirement from BioCryst‘s Board of Directors, effective at the 2025 Annual Meeting. The company expressed gratitude for his 13 years of service. On June 12, 2025, BioCryst’s stockholders approved an amendment to the Stock Incentive Plan, increasing available shares by 11 million. The meeting also included the election of directors, ratification of Ernst & Young LLP as accountants, and approval of executive compensation.
The most recent analyst rating on (BCRX) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.
BioCryst Pharmaceuticals extended a Consulting Agreement with its former CFO, Anthony Doyle, to ensure a smooth transition in leadership. The agreement, effective April 9, 2025, and extended on May 31, 2025, will continue on a month-to-month basis after December 31, 2025, providing stability during the CFO transition.
The most recent analyst rating on (BCRX) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.
On May 14, 2025, BioCryst Pharmaceuticals announced that the FDA accepted its new drug application for ORLADEYO® oral granules for pediatric patients with hereditary angioedema aged 2 to 11 years, granting it priority review with a target action date of September 12, 2025. If approved, ORLADEYO would be the first targeted oral prophylactic therapy for this age group, potentially improving disease management and reducing acute attacks, with additional regulatory filings planned in Europe, Japan, and Canada.
The most recent analyst rating on (BCRX) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.
BioCryst Pharmaceuticals reported a strong financial performance for the first quarter of 2025, with ORLADEYO net revenue reaching $134.2 million, a 51% increase year-over-year. The company has increased its full-year revenue guidance for ORLADEYO to between $580 million and $600 million and expects to achieve profitability a year ahead of schedule. BioCryst is also advancing its pipeline with a new drug application for ORLADEYO oral granules for children with HAE and clinical trials for treatments targeting Netherton syndrome and diabetic macular edema. The company paid down $75 million of debt, saving approximately $23.5 million over the life of the loan, and plans to continue investing in its pipeline while maintaining financial growth.
On April 30, 2025, BioCryst Pharmaceuticals announced the expansion of its Board of Directors from ten to eleven members, with the election of Steven Frank, effective May 2, 2025. Mr. Frank, a respected healthcare investment banker, is expected to bring valuable expertise to the board as BioCryst aims to build on its commercial success and advance its pipeline. The appointment highlights BioCryst’s strategic focus on accelerating towards profitability and enhancing its position in the biopharma industry.
On February 28, 2025, BioCryst Pharmaceuticals announced the resignation of its Chief Financial Officer and Interim Principal Accounting Officer, Anthony Doyle, effective April 9, 2025. To ensure a smooth transition, Doyle will provide consulting services until May 31, 2025. Subsequently, on April 7, 2025, the company’s Board appointed CEO Jon P. Stonehouse as the Interim CFO and Interim Principal Accounting Officer. The company has also engaged a former biotechnology CFO as a consultant to assist during the transition while searching for a permanent CFO.